Hikma agrees to acquire Xellia Pharmaceuticals’ assets for $135 million
LONDON: Hikma Pharmaceuticals has agreed with Copenhagen based Xellia Pharmaceuticals to acquire parts of its US finished dosage form (FDF) business and assets, including a...